Now Available: Diagnostics Year in Review 2023. Click to Download Report.
A recent meta-analysis published in JAMA Internal Medicine (August 2023) found no evidence that the most common types of cancer screening are providing statistically significant benefits in overall survival, with the exception of colorectal cancer screening with sigmoidoscopy. How can this be?
Actym Therapeutics, pioneering a new drug modality to treat solid tumors, announced today it has extended its Series A financing round with an additional close of $25.5 million, bringing the total Series A amount raised to $59.5 million.
Precede Biosciences emerges from stealth today with a breakthrough, comprehensive, blood-based approach to revealing disease-defining transcriptional biology – a first for the diagnostic field.
Iambic’s unique AI-Driven drug-discovery platform identifies potential first-in-class and best-in-class development candidates years faster than industry norms. Funding will support continued AI platform innovations and advancement of multiple candidates into clinical development, Including IAM-H1, a selective brain-penetrant HER2 Inhibitor, and IAM-C1, a selective dual CDK2/4 inhibitor.
Your screen does not meet the requirements for generating previews. Adjust your screen width to exactly 1920px before proceeding, otherwise you'll not be able to generate previews.
